Labopharm Inc - Premium Company Profile
Labopharm Inc - Premium Company Profile - New Research Report on Companies and Markets
© companiesandmarkets.com
14.11.2008 23:59:01 www.companiesandmarkets.com adds new report - Labopharm Inc - Premium Company Profile
(live-PR.com) - www.companiesandmarkets.com/Summary-Company-Prof ..
Introduction
Labopharm, formerly known as Centre de Recherche Appliquee Pharmaceutique (CRAP), is a specialty pharmaceutical company optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies: Contramid and PNDS. . It is currently focusing on developing and commercializing its lead product candidate, Trazodone for the potential treatment of depression.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed
business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Labopharm´s primary focus is developing small molecule drugs for two therapeutic indications, pain and depression. The company currently has one marketed product, Tramadol, indicated for moderate to severe pain, in Europe and Canada through its marketing partners. Trazodone, indicated for depression is currently in Phase III clinical development.
The company´s total revenues increased at a CAGR of 102.9% during 2002-2006, from $0.8 million to $14 million. This represents an absolute total growth of +$13.1 million for total revenues during the same period. License, collaboration and other revenues are a major contributor to revenue growth by contributing +$7.1 million.
The company´s biggest contributor to sales growth out to 2010 again will be revenues from license, collaboration and other. Revenues from license, collaboration and other are expected to increase from $8 million in 2006 to $75 million in 2010, recording an absolute growth of +$67 million.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
Introduction
Labopharm, formerly known as Centre de Recherche Appliquee Pharmaceutique (CRAP), is a specialty pharmaceutical company optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies: Contramid and PNDS. . It is currently focusing on developing and commercializing its lead product candidate, Trazodone for the potential treatment of depression.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed
|
|
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Labopharm´s primary focus is developing small molecule drugs for two therapeutic indications, pain and depression. The company currently has one marketed product, Tramadol, indicated for moderate to severe pain, in Europe and Canada through its marketing partners. Trazodone, indicated for depression is currently in Phase III clinical development.
The company´s total revenues increased at a CAGR of 102.9% during 2002-2006, from $0.8 million to $14 million. This represents an absolute total growth of +$13.1 million for total revenues during the same period. License, collaboration and other revenues are a major contributor to revenue growth by contributing +$7.1 million.
The company´s biggest contributor to sales growth out to 2010 again will be revenues from license, collaboration and other. Revenues from license, collaboration and other are expected to increase from $8 million in 2006 to $75 million in 2010, recording an absolute growth of +$67 million.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
| Author: |
